18889881171
Kalkine 0
countryflagUS

Alvotech Warrant

Healthcare US ALVOW

1.59USD
-0.06(3.64%)

Last update at 2025-07-15T16:02:00Z

Day Range

1.591.68
LowHigh

52 Week Range

1.886.31
LowHigh

Fundamentals

  • Previous Close 1.65
  • Market Cap0.00000M
  • Volume2011
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-104.55100M
  • Revenue TTM308.73M
  • Revenue Per Share TTM1.28
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -551.64700M -149.19800M -291.77000M -209.38500M
Minority interest - - - -
Net income -513.58000M -101.50400M -170.04400M -209.87600M
Selling general administrative 186.74M 84.13M 58.91M 48.57M
Selling and marketing expenses - - - -
Gross profit 18.93M 36.77M 66.62M 31.92M
Reconciled depreciation 20.41M 18.20M 16.42M 14.61M
Ebit -346.44200M -235.45600M -137.53700M -61.44800M
Ebitda -326.07400M -168.11000M -125.67000M -48.11300M
Depreciation and amortization 20.37M 67.35M 11.87M 13.34M
Non operating income net other - - - -
Operating income -346.44200M -235.45600M -137.53700M -61.44800M
Other operating expenses 429.47M 272.23M 204.15M 93.37M
Interest expense 188.42M 117.36M 97.47M 95.75M
Tax provision -38.06700M -47.69400M -121.72600M 0.49M
Interest income 0.91M 0.02M 0.21M 1.74M
Net interest income -90.52600M -114.53800M -100.51300M -96.83500M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -38.06700M -47.69400M -121.72600M 0.49M
Total revenue 83.03M 36.77M 66.62M 31.92M
Total operating expenses 365.38M 272.23M 204.15M 93.37M
Cost of revenue 64.09M - 0.00000M -
Total other income expense net -205.20500M 86.26M -154.23300M -147.93700M
Discontinued operations - - - -
Net income from continuing ops -513.58000M -101.50400M -170.04400M -209.87600M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 950.09M 828.44M 597.98M 474.42M -
Intangible assets 19.08M 25.65M 21.51M 6.33M -
Earning assets - - - - -
Other current assets 22.04M 32.95M 9.32M 5.92M -
Total liab 1882.58M 1392.86M 733.59M 1341.66M -
Total stockholder equity -932.49300M -564.41600M -135.61200M -867.24300M -
Deferred long term liab - - - - -
Other current liab 73.50M 56.11M 43.49M 16.85M -
Common stock 2.28M 2.13M 0.14M 0.07M -
Capital stock 2.28M 2.13M 0.14M 0.07M -
Retained earnings -2205.84500M -1654.11400M -1140.53400M -1039.03000M -
Other liab - - - - -
Good will 12.06M 11.64M 12.37M 13.43M -
Other assets - - - - -
Cash 11.16M 66.43M 17.56M 31.69M -
Cash and equivalents - - - - -
Total current liabilities 260.95M 167.29M 111.84M 50.98M -
Current deferred revenue 59.18M 36.91M 29.69M 14.19M -
Net debt 1064.32M 738.67M 505.50M 645.16M -
Short term debt 47.71M 25.08M 10.07M 7.98M -
Short long term debt 38.02M 19.92M 2.77M 2.50M -
Short long term debt total 1075.47M 805.10M 523.05M 676.85M -
Other stockholder equity 1229.69M 1058.43M 1000.12M 166.74M -
Property plant equipment - - - - -
Total current assets 194.84M 230.74M 119.82M 86.16M -
Long term investments 18.49M 48.57M 55.31M 56.68M -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 87.22M 59.89M 53.88M 38.90M -
Long term debt 922.13M 744.65M 398.14M 565.40M -
Inventory 74.43M 71.47M 39.06M 9.65M -
Accounts payable 80.56M 49.19M 28.59M 11.96M -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 41.38M 29.14M 4.67M 4.97M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 39.23M 34.25M 13.23M 12.99M -
Deferred long term asset charges - - - - -
Non current assets total 755.25M 597.71M 478.16M 388.26M -
Capital lease obligations 115.31M 40.53M 122.14M 108.95M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -63.53700M -40.63300M -16.90300M -12.87600M
Change to liabilities - - - -
Total cashflows from investing activities - - - -
Net borrowings - - - -
Total cash from financing activities 424.91M 254.83M 55.40M 116.37M
Change to operating activities - - - -
Net income -513.58000M -101.50400M -170.04400M -209.87600M
Change in cash 48.87M -14.13300M -35.71400M 15.15M
Begin period cash flow 17.56M 31.69M 67.40M 52.25M
End period cash flow 66.43M 17.56M 31.69M 67.40M
Total cash from operating activities -312.38900M -228.17000M -74.29500M -88.54800M
Issuance of capital stock 0.00000M 185.86M 34.38M 30.69M
Depreciation 20.41M 18.20M 16.42M 14.61M
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory -32.41200M -29.41200M -3.25500M -4.16300M
Change to account receivables -3.57600M -28.81300M 21.77M -21.94700M
Sale purchase of stock - - - -
Other cashflows from financing activities 520.77M 113.82M 30.00M 113.83M
Change to netincome - - - -
Capital expenditures 49.00M 40.63M 11.98M 8.05M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital -47.89000M -6.80700M 32.52M -13.83500M
Stock based compensation 10.32M -22.32100M -5.46000M -8.85400M
Other non cash items 256.42M -68.04000M 174.00M 128.92M
Free cash flow -361.39100M -268.80300M -86.27700M -96.60000M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
ALVOW
Alvotech Warrant		 -0.06 3.64% 1.59 - - - -
ZTS
Zoetis Inc		 -1.98 1.27% 153.67 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.16 0.62% 25.62 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -1.45 1.14% 125.37 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.3 1.99% 14.74 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Alvotech Warrant

9, Rue de Bitbourg, Luxembourg City, Luxembourg, 1273

Key Executives

Name Title Year Born
Mr. Robert Wessman Exec. Chairman of Directors 1970
Mr. Mark Levick Chief Exec. Officer 1964
Mr. Joel Morales Chief Financial Officer 1978
Mr. Sean Gaskell Chief Technical Officer 1982
Mr. Joseph E. McClellan Chief Scientific Officer 1974
Ms. Sigridur Elin Gudlaugsdottir VP of HR NA
Ms. Tanya Zharov Deputy Chief Exec. Officer 1967
Ms. Reem Malki Chief Quality Officer 1971
Mr. Anil Okay Chief Commercial Officer 1986
Mr. Ming Li Chief Strategy Officer 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.